We have built a diverse pipeline of NOX inhibitors. Preclinical studies show that NOX1&4 inhibitors have broad potential across fibrotic and inflammatory diseases of the kidney, liver, lungs and skin.

In addition to our NOX1&4 inhibitors, we have earlier-stage programs for other indications based on inhibition of different NOX isoforms. We continue to apply our unique screening platform to further discover new NOX inhibitors with different profiles to address diseases where there is high unmet need.

Pipeline jan2019 023bb